Noxopharm Announced $8.1 Million Capital Raise to Advance Noxopharm Veyonda® & Capital Structure

  • Feb 14, 2020 AEDT
  • Team Kalkine

Noxopharm (ASX: NOX) announced the capital raising of $8.1 million which comprise of $3.1 million equity placement and a $5 million loan.

The proceeds would be used for progressing the Noxopharm Veyonda® clinical programs which include planning of the multi-national DARRT-2 study, and to allow retirement of convertible note funding facility.


All pictures are copyright to their respective owner(s) does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK